Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 15;217(9):e20192080. doi: 10.1084/jem.20192080

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Mahuron et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 3. — Layilin augments CD8⁺ TIL-mediated antitumor immunity. (A) Layn^−/− or wild-type animals were injected subcutaneously with the MC38 tumor cell line and tumor growth quantified by caliper measurements. Symbols and error bars represent mean and SEM at each time point; n = 7 per group. Data are representative of two independent experiments. (B) CD8^creLayn^f/f and CD8^creLayn^wt/wt mice were injected subcutaneously with B16.F10 or MC38 tumor cell lines. Symbols and error bars represent mean and SEM at each time point; n = 6–10 per group. Data are representative of three independent experiments. (C) Representative images and quantification of in vivo luciferin bioluminescence imaging taken of mice bearing MC38-LUC2 tumors. Symbols correspond to individual mice. Statistical significance was determined by two-way ANOVA (A and B) or unpaired two-tailed t tests (C). *, P < 0.05; ****, P < 0.0001.